BTIG Says Abiomed (ABMD) Is A Top Pick For 2017

BTIG maintains Buy on ABIOMED (NASDAQ: ABMD), price target of $170.00.

Analyst Sean Lavin commented "Very simply, we think in 2017 Abiomed is in an enviable position of experiencing continuing momentum within its existing markets, having no real direct competition, penetration into a new market (Japan), and benefiting from more favorable reimbursement. Longer term ABMD may have a new market in non shock MI depending on how trials this year and in the future play
out.

For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.

Shares of ABIOMED closed at $114.81 yesterday.

You May Also Be Interested In

• Chipotle Mexican Grill (CMG) PT Raised to $3,350 at BTIG
• Needham Upgrades Silicon Labs (SLAB) to Buy
• JPMorgan Upgrades Doximity Inc (DOCS) to Neutral 'Given a More Stabilized Macro Backdrop and Little Downside to Our Valuation'